Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Feb
15
2022
The Joint Commission Announces COVID-19 Vaccine Surveys Have Begun Robinson & Cole LLP
Jun
9
2023
Connecticut Governor’s Health Care Bill Makes Important Changes to the Certificate of Need Process Robinson & Cole LLP
Feb
6
2019
HHS Proposes to Amend AKS Safe Harbors to Exclude PBM Rebates and Incentivize Consumer Drug Discounts Robinson & Cole LLP
May
29
2019
Legal Pot = Storm Clouds for Manufacturers Robinson & Cole LLP
Mar
23
2020
COVID-19: HHS Issues FAQs on HIPAA and Telehealth to Help Providers Maintain Access to Care During the Pandemic Robinson & Cole LLP
Dec
15
2020
Supreme Court Rules that ERISA Does Not Preempt State Law Regulating PBM Reimbursements Robinson & Cole LLP
Aug
5
2021
Maine Requires Companies to Pay For Their Packaging Robinson & Cole LLP
Nov
16
2021
HHS Again Requires FDA Premarket Review for COVID-19 Tests Robinson & Cole LLP
Feb
15
2022
The Joint Commission Announces COVID Vaccine Surveys Have Begun Robinson & Cole LLP
Nov
4
2023
Privacy Tip #378 – Bad Actors Selling Data of 23andMe Users of Ashkenazi Jewish and Chinese Descent Robinson & Cole LLP
Apr
8
2019
CBD Update: FDA Issues Statement, Calls Public Hearing, and Announces Warning Letters on Products Containing Cannabis and its Components Robinson & Cole LLP
Jun
4
2019
OIG Issues Alert to Warn of ‘Free’ Genetic Testing Scams Seeking to Steal Information Robinson & Cole LLP
Sep
3
2019
Spurred by Opioid Crisis, Government Proposes Additional Changes to Substance Use Disorder Confidentiality Regulations to Facilitate Provision of Coordinated Care Robinson & Cole LLP
Jan
9
2023
2023 Labor and Employment Outlook for Manufacturers Robinson & Cole LLP
May
12
2023
DEA Extends Pandemic Telehealth Prescribing Flexibilities For Up To 18 Months Robinson & Cole LLP
Jun
13
2023
Connecticut Health Care Bill Revises Provider-Payor Contracting Requirements to Address Competitive Concerns Robinson & Cole LLP
Mar
25
2020
Rhode Island Issues Emergency Regulations on Off-Label Prescribing for COVID-19, and Guidance on Telehealth and Reciprocal Licensure Robinson & Cole LLP
Mar
26
2020
Massachusetts Issues COVID-19 Orders and Related Guidance for Pharmacies and Pharmacy Professionals Robinson & Cole LLP
May
6
2021
Girl Scout Troop Teams Up with Wing for Drone Cookie Deliveries Robinson & Cole LLP
Apr
4
2019
Medical Marijuana Delivery App Agrees to Settle TCPA Case for $1.75M Robinson & Cole LLP
Oct
31
2019
Legal Pot = Manufacturing Storm Clouds (the Refrain) Robinson & Cole LLP
Mar
16
2023
As COVID-19 Emergency Waivers End, DEA Proposes to Expand Tele-Prescribing of Controlled Substances Robinson & Cole LLP
Nov
5
2020
ShopRite Settles with NJ AG for Data Breach Robinson & Cole LLP
Apr
17
2024
Weight Loss, Miracle Medications & the Workplace Robinson & Cole LLP
Oct
21
2021
EPA Releases PFAS Strategic Roadmap - October 21, 2021 Robinson & Cole LLP
Jan
31
2019
OIG Advisory Opinion No. 19-02 Allows Pharmaceutical Manufacturer to Temporarily Loan Smartphones to Financially Needy Patients to Receive Data from a Digestible Medication Sensor Robinson & Cole LLP
Oct
25
2022
Advisory Opinion 22-19: OIG Warns That Proposed Drug Cost Subsidization Arrangement May Warrant Sanctions Robinson & Cole LLP
Jan
28
2020
DOJ Reaches Settlement with Patient Assistance Foundation Resolving Allegations of FCA Violations Robinson & Cole LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins